Navigation Links
Nile Therapeutics to Transition to OTCQB Marketplace
Date:5/11/2011

SAN MATEO, Calif., May 11, 2011 /PRNewswire/ -- Nile Therapeutics, Inc. (NASDAQ: NLTX), a biopharmaceutical company that develops novel therapeutics for heart failure patients, today announced that the Company's securities will cease trading on The Nasdaq Capital Market effective with the open of business on May 12, 2011.  The Company expects its common stock to begin trading under the "NLTX" symbol on the OTCQB Marketplace following the suspension of trading on the Nasdaq Capital Market.

As previously disclosed, on November 30, 2010, the Company was notified by The NASDAQ Stock Market ("NASDAQ") that its securities were subject to delisting based upon the Company's failure to satisfy NASDAQ's minimum $1.00 bid price requirement, as set forth in Listing Rule 5550(a)(2).  The Company subsequently attended a hearing before the NASDAQ Listing Qualifications Panel (the "Panel") at which it presented its plan to regain compliance with the minimum bid price requirement by May 31, 2011, one component of which consisted of effecting a reverse stock split.  On March 1, 2011, the Panel granted the Company's request for an extension to remain listed on NASDAQ, subject to the Company evidencing a closing bid price of at least $1.00 per share for a minimum of ten consecutive business days by May 31, 2011 and demonstrating compliance with all other applicable listing standards as of such date.  On May 10, 2011, the Company informed NASDAQ that it had determined not to proceed with a reverse stock split prior to May 31, 2011.  Accordingly, on May 10, 2011, the Company was notified by NASDAQ that trading in its securities on would be suspended on The Nasdaq Capital Market as of the open of business on May 12, 2011, with formal delisting to follow.

Operated by OTC Markets Group Inc., the OTCQB is a market tier for OTC traded companies that are registered
'/>"/>

SOURCE Nile Therapeutics, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Halozyme Therapeutics Reports First Quarter 2011 Financial Results
2. InVivo Therapeutics and The Miami Project to Cure Paralysis Form Strategic Research Collaboration to Develop Novel Treatments for Spinal Cord Injuries
3. Talecris Biotherapeutics Announces Results of Annual Stockholders Meeting
4. Silence Therapeutics Issued Japanese Patent Covering its Core RNA Interference (RNAi) Technology
5. Cell Therapeutics Retires 7.5% Convertible Senior Notes
6. Talecris Biotherapeutics Announces First Quarter 2011 Results
7. Nektar Therapeutics Reports First Quarter 2011 Financial Results
8. Carmell Therapeutics Completes Series A Financing to Advance the Development of Novel Bioactive Plastics
9. Proteon Therapeutics Initiates Patient Enrollment in Phase 2 Clinical Study of PRT-201 in Hemodialysis Patients
10. Talecris Biotherapeutics to Report First Quarter 2011 Financial Results
11. Precision Therapeutics ChemoFx® Demonstrates Significant Role in Selection of Chemotherapy Doublets in Non Small Cell Lung Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/21/2014)... 2014 Lawrence Livermore National ... (WIB) and Las Positas College (LPC) recently established ... and hands-on training for veterans, officials recently announced. ... Las Positas is designed to help veterans ... technician careers, and establishes a pipeline of qualified ...
(Date:7/21/2014)... a chain of carbon atoms can turn it from ... University scientists. , Stretching the material known as carbyne ... by just 3 percent can begin to change its ... mechanically activated nanoscale electronics and optics. , The finding ... appears in the American Chemical Society journal Nano ...
(Date:7/21/2014)... EUGENE, Ore. (July 21, 2014) The yield ... of Oregon have developed a low-energy, solution-based mineral substitution ... that could find use in electronics and alternative energy ... on the cover of the July 21 issue of ... most citations of research in the inorganic and nuclear ...
(Date:7/21/2014)... York , July 21, 2014 ... on Global & USA ... Trends, and Forecasts ResearchMoz presents this ... Biomaker Market   to 2018 (Identification, Technologies, Market Analysis, ... Trends, and Pipeline Analysis. GLOBAL & ...
Breaking Biology Technology:Engineering Program Established for Veterans 2Engineering Program Established for Veterans 3Carbyne morphs when stretched 2Carbyne morphs when stretched 3Oregon chemists eye improved thin films with metal substitution 2Global & USA Cancer Biomaker Market to 2018 (Identification, Technologies, Market Analysis, Competitor Profiles, Companion Diagnostic Co-Development, Business Strategies, Industry Trends, and Pipeline Analysis) - Market Size, Trends, and Forecasts A 2Global & USA Cancer Biomaker Market to 2018 (Identification, Technologies, Market Analysis, Competitor Profiles, Companion Diagnostic Co-Development, Business Strategies, Industry Trends, and Pipeline Analysis) - Market Size, Trends, and Forecasts A 3Global & USA Cancer Biomaker Market to 2018 (Identification, Technologies, Market Analysis, Competitor Profiles, Companion Diagnostic Co-Development, Business Strategies, Industry Trends, and Pipeline Analysis) - Market Size, Trends, and Forecasts A 4Global & USA Cancer Biomaker Market to 2018 (Identification, Technologies, Market Analysis, Competitor Profiles, Companion Diagnostic Co-Development, Business Strategies, Industry Trends, and Pipeline Analysis) - Market Size, Trends, and Forecasts A 5Global & USA Cancer Biomaker Market to 2018 (Identification, Technologies, Market Analysis, Competitor Profiles, Companion Diagnostic Co-Development, Business Strategies, Industry Trends, and Pipeline Analysis) - Market Size, Trends, and Forecasts A 6
... Oncology Biomarkers, FREMONT, Calif., Feb. 6 ... high-value molecular diagnostics company, today announced,the renewal ... University,on the development of novel biomarkers that ... monitoring of prevalent cancers, including,ovarian, breast and ...
... BRL ) today announced that its subsidiary, Barr ... Co., Inc.,s Fosamax(R),(Alendronate Sodium) Tablets, 70 mg after receiving ... The FDA approved the Company,s application on February ... the,earliest to expire of the patents listed with the ...
... 6 Iomai Corporation,(Nasdaq: IOMI ) today announced ... officer, will present at the 10th Annual BIO,CEO & ... 12. Mr. Erck,s,presentation will begin at 2 p.m. Eastern ... Mr. Erck will give an update on corporate ...
Cached Biology Technology:Vermillion and Johns Hopkins Sign Collaborative Research and License Agreements to Develop Molecular Diagnostic Tests 2Barr Launches Generic Fosamax(R) Tablets, 70 mg 2Barr Launches Generic Fosamax(R) Tablets, 70 mg 3Barr Launches Generic Fosamax(R) Tablets, 70 mg 4Iomai CEO to Speak at BIO CEO & Investor Forum on Feb. 12 2
(Date:7/22/2014)... showed that mutations in prickle genes cause epilepsy, ... by repeated seizures over time. However, the mechanism ... A new University of Iowa study, published online ... National Academy of Sciences , reveals a novel ... have identified the basic cellular mechanism that goes ...
(Date:7/22/2014)... research in the Journal of Clinical ... signaling and dopamine transporter function are linked ... Parkinsonism and attention deficit hyperactivity disorder (ADHD). ... critical basis for further exploration of how ... contribute to brain disorders" said Michelle Sahai, ...
(Date:7/22/2014)... on July 14, 2014, by lightning from a weather system ... of four fires: Stokes Fire, Gold Hikes Fire, French Creek ... fires are now one larger fire. The fires are burning ... over 243,000 acres in size. The present fire situation ... Public and firefighter safety is the priority on the Carlton ...
Breaking Biology News(10 mins):UI study finds potential genetic link between epilepsy and neurodegenerative disorders 2The dopamine transporter 2The dopamine transporter 3
... from early hominid to dominant species, is the defining ... To chronicle this epic narrative an internationally renowned team, ... University, presents the Wiley-Blackwell Encyclopedia of Human Evolution, a ... history. Over two volumes and 5000 entries ...
... Boston, MA - Some 25 million people in the United ... diseases characterized by often debilitating pain in the joints. Now ... gel that could spell the future for treating these diseases ... the targeted release of medicine at an affected joint, and ...
... crustaceans called copepods rule the world, at least when ... numerous multi-cellular organisms in the seas, copepods are an ... webs. To understand and predict how copepods respond ... how many new copepods are born, but how many ...
Cached Biology News:Injectable gel could spell relief for arthritis sufferers 2Injectable gel could spell relief for arthritis sufferers 3Death -- not just life -- important link in marine ecosystems 2
... Schistosomal glutathione-S-transferase (GST) is commonly used ... in E. coli (1). The GSTTag sequence ... and in some cases the solubility of ... soluble, properly folded form, GSTTag fusion proteins ...
... your samples with eArray and Agilents custom printing. ... own microarray designs that meet your specific biological ... delivery of your arrays in weeks, anywhere in ... creation application tool that enables you to design ...
Acetylcholinesterase (human brain, AChE)...
... 7500ce meets the demands of the routine ... performance from reliable, robust and simple to ... power in the most challenging sample matrices ... equally suited to the toughest analytical challenges ...
Biology Products: